At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
AUR101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized, Study to Evaluate the Efficacy and Safety of Two Doses of AUR101 in Patients With Moderate-to-Severe Psoriasis
In Brief
A Phase 2 clinical trial evaluating AUR101 and Matching Placebo for Chronic Plaque-type Psoriasis. Completed, enrolled 90 participants across 9 sites.
Detailed Summary
This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate efficacy and safety of AUR101 (RORgamma inhibitor) in patients with moderate-to-severe psoriasis. Approximately 90 patients with chronic moderate-to-severe plaque psoriasis will be randomized to the 2 dose groups of AUR101 and one group of Placebo. The patients will receive the treatment for 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque-type Psoriasis
CountriesIndia
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartJan 2020
Primary CompletionMar 2021
Study CompletionApr 2021
TodayJul 2026
First PostedDec 23, 2019
Enrollment StartJan 21, 2020
Primary CompletionMar 20, 2021
Study CompletionApr 15, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.5 years ago
Interventions
AUR101drug
Inhibitor of RORγ
Matching Placebodrug
Drug-Placebo of AUR101 tablet